Ponnoth DS, Nayeem MA, Kunduri SS, Tilley SL, Zeldin DC, Ledent C, Mustafa SJ. Role of -hydroxylase in adenosine-mediated aortic response through MAP kinase using A 2A receptor knockout mice. Am J Physiol Regul Integr Comp Physiol 302: R400 -R408, 2012. First published December 7, 2011; doi:10.1152/ajpregu.00481.2011.-Previously, we have shown that A2A adenosine receptor (A2AAR) knockout mice (KO) have increased contraction to adenosine. The signaling mechanism(s) for A2AAR is still not fully understood. In this study, we hypothesize that, in the absence of A2AAR, -hydroxylase (Cyp4a) induces vasoconstriction through mitogen-activated protein kinase (MAPK) via upregulation of adenosine A1 receptor (A1AR) and protein kinase C (PKC). Organ bath and Western blot experiments were done using isolated aorta from A2AKO and corresponding wild-type (WT) mice. Isolated aortic rings from WT and A2AKO mice were precontracted with submaximal dose of phenylephrine (10 Ϫ6 M), and concentration responses for selective A1AR, A2AAR agonists, angiotensin II and cytochrome P-450-epoxygenase, 20-hydroxyeicosatrienoic acid (20-HETE) PKC, PKC-␣, and ERK1/2 inhibitors were obtained. 2-p-(2-Carboxyethyl)-phenethylamino-5=-N-ethylcarboxamidoadenosine hydrochloride (CGS-21680, A 2AAR agonist) induced concentration-dependent relaxation in WT, which was blocked by methylsulfonyl-propargyloxyphenylhexanamide (cytochrome P-450-epoxygenase inhibitor; 10 Ϫ5 M) and also with removal of endothelium. A1 agonist, 2-chloro-N 6 -cyclopentyladenosine (CCPA) produced higher contraction in A2AKO aorta than WT (49.2 Ϯ 8.5 vs. 27 Ϯ 5.9% at 10 Ϫ6 M, P Ͻ 0.05). 20-HETE produced higher contraction in A 2AKO than WT (50.6 Ϯ 8.8 vs. 21.1 Ϯ 3.3% at 10 Ϫ7 M, P Ͻ 0.05). Contraction to CCPA in WT and A2AKO aorta was inhibited by PD-98059 (p42/p44 MAPK inhibitor; 10 Ϫ6 M), chelerythrine chloride (nonselective PKC blocker; 10 Ϫ6 M), Gö-6976 (selective PKC-␣ inhibitor; 10 Ϫ7 M), and HET0016 (20-HETE inhibitor; 10 Ϫ5 M). Also, contraction to 20-HETE in WT and A2AKO aorta was inhibited by PD-98059 and Gö-6976. Western blot analysis indicated the upregulation of A 1AR, Cyp4a, PKC-␣, and phosphorylated-ERK1/2 in A2AKO compared with WT (P Ͻ 0.05), while expression of Cyp2c29 was significantly higher in WT. CCPA (10 Ϫ6 M) increased the protein expression of PKC-␣ and phosphorylated-ERK1/2, while HET0016 significantly reduced the CCPA-induced increase in expression of these proteins. These data suggest that, in the absence of A2AAR, Cyp4a induces vasoconstriction through MAPK via upregulation of A1AR and PKC-␣. adenosine receptors; relaxation; contraction; cytochrome p4504a; extracellular signal-regulated kinase-1/2 kinases ADENOSINE REGULATES VASCULAR tone through four adenosine receptor (AR) subtypes i.e., A 1 , A 2A , A 2B , and A 3 (42). The response produced in vasculature depends, in part, on the subtype of receptor activated, leading to either vasoconstriction or vasorelaxation. Activation of the A 1 AR and A 3 AR causes contraction, whereas A 2A AR and A 2B AR cause relaxation (2, 10, 12, 17, 25, 41, 43, 44) . We have shown that the lack of A 2A AR markedly lowers adenosine-mediated vascular relaxation and that cytochrome P-450 (CYP) epoxygenases play a role in A 2A -induced vascular relaxation (27, 32) .
ADENOSINE REGULATES VASCULAR tone through four adenosine receptor (AR) subtypes i.e., A 1 , A 2A , A 2B , and A 3 (42) . The response produced in vasculature depends, in part, on the subtype of receptor activated, leading to either vasoconstriction or vasorelaxation. Activation of the A 1 AR and A 3 AR causes contraction, whereas A 2A AR and A 2B AR cause relaxation (2, 10, 12, 17, 25, 41, 43, 44) . We have shown that the lack of A 2A AR markedly lowers adenosine-mediated vascular relaxation and that cytochrome P-450 (CYP) epoxygenases play a role in A 2A -induced vascular relaxation (27, 32) .
Metabolites of arachidonic acid (AA), produced by the endothelium, are known to regulate vascular tone. Epoxyeicosatrienoic acids (EETs) are metabolites of AA, formed through the action of CYP epoxygenases, including Cyp2c29, which have been proposed to be an endothelium-derived hyperpolarizing factor (EDHF) (9) . Activation of A 2A AR is related to increased activity of CYP epoxygenase that results in vasorelaxation (6, 27) . We also found an upregulation of Cyp2c29 associated with the presence of A 2A AR that caused endothelium-dependent relaxation (27) .
On the other hand, 20-hydroxyeicosatrienoic acid (20-HETE), a -hydroxylation product of AA catalyzed by Cyp4a, is a potent vasoconstrictor (36) . Several studies have shown a link between vascular 20-HETE generation and responses in various vascular beds, including renal, cerebral, skeletal, and mesenteric (7, 8, 18) . Increase in intracellular Ca 2ϩ in smooth muscle causes an increase in 20-HETE (13) , and, subsequent to this, 20-HETE inhibits Ca 2ϩ -dependent K ϩ channels, resulting in increase in vascular tone (14) .
Previously, we have found that, in A 2A knockout (KO) aorta, the use of A 1 -selective antagonist blunted the contraction response, suggesting a role for A 1 AR-mediated contraction (32) . A 1 AR is coupled to G i/o proteins, and its activation results in a decrease in cyclic AMP through inhibition of adenylate cyclase (20) . Studies have also shown that A 1 AR activates p42/44 MAPK (ERK1/2) in vascular tissue and different cell lines (4, 16, 37) . This activation may involve protein kinase A, protein kinase C (PKC), Src tyrosine kinase, or Ras activation (30, 38) .
Studies from this laboratory have also found that several PKC isoforms are upregulated in porcine coronary artery smooth muscle cells through A 1 AR upregulation, which is blocked by pertussis toxin (19, 21) . More recently, our laboratory has published reports that indicate that A 1 AR causes PKC-␣ activation, leading to p42/p44 MAPK phosphorylation in mouse coronary artery smooth muscle cells from wild-type (WT) and A 1 KO that also causes vascular contraction in mesenteric arteries (4). 20-HETE has also been linked with the activation of PKC (14, 36) . Therefore, we hypothesize that, in the absence of A 2A AR, Cyp4a-derived metabolite, 20-HETE induces vasoconstriction through MAPK via upregulation of A 1 AR and PKC-␣.
MATERIALS AND METHODS
Animals. A2AKO mice (originally from C. Ledent, Universite Libre de Bruxelles, Brussels, Belgium) were obtained from Dr. Stephen Tilley, University of North Carolina Chapel Hill, on C57BL/6J background. C57BL/6J (WT) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). A 2AKO mice were backcrossed 12 generations to the C57BL/6J background. A2AKO mice were generated and genotyped by polymerase chain reaction. Males and females 14 -18 wk old were used in our studies. All experimental animals used in this study were under a protocol approved by the Institutional Animal Care and Use Committee of West Virginia University.
Preparation of isolated mouse aorta and isometric force measurement. Mice were killed by anesthesia with pentobarbital sodium (65 mg/kg ip), followed by thoracotomy and removal of aorta that was then cut transversely into 3-to 4-mm rings. The rings were mounted vertically between two stainless steel wire hooks and then suspended in 10-ml organ baths containing Krebs-Henseleit buffer. The Krebs-Henseleit buffer (pH 7.4), containing 118 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO 4, 1.2 mM KH2PO4, 25 mM NaHCO3, 11 mM glucose, and 2.5 mM CaCl2, was maintained at 37°C with continuous bubbling of 95% O2 and 5% CO2. For measurement of isometric force response, aortic rings were equilibrated for 90 min with a resting force of 1 g and change of the bathing solution at 15-min interval. The resting force of 1 g has been used earlier in our laboratory and was determined using a length-tension relationship (2, 31, 43) . At the end of the equilibration period, tissues were contracted with 50 mM KCl to check the contractility of individual aortic rings twice, which were washed out with Krebs-Henseleit buffer. Aortic rings were then constricted with phenylephrine at submaximal concentration (PE, 10 Ϫ6 M) to obtain a steady contraction, and changes in tension were monitored continuously with fixed range precision force transducer (TSD, 125 C, BIOPAC system) connected to the differential amplifier (DA 100B, BIOPAC system). The data were recorded using MP100, BIOPAC digital acquisition system and analyzed using Acknowledge 3.5.7 software (BIOPAC system).
Contraction/relaxation experiments. After equilibration, the responsiveness and stability of individual rings were checked by successive administration of PE (10 Ϫ6 M). The integrity of the vascular endothelium was assessed pharmacologically by acetylcholine (10 Ϫ6 M) to produce relaxation of PE precontracted rings. Aortic rings were then washed several times with Krebs-Henseleit solution and allowed to equilibrate for 30 min before the experimental protocol began. In experiments in which the involvement of endothelium was investigated, endothelium was removed mechanically before mounting in the bath, using a thin stainless steel wire to scrape the lumen of the aorta.
Experimental protocol. The concentration-response to 2-p-(2-carboxyethyl)-phenethylamino-5=-N-ethylcarboxamidoadenosine hydrochloride (CGS-21680; 10 Ϫ11 -10 Ϫ6 M), 2-chloro-N 6 -cyclopentyladenosine (CCPA; 10 Ϫ11 -10 Ϫ6 M), and angiotensin II (10 Ϫ11 -10 Ϫ5 M) were run in parallel in aortic rings from WT and A2AKO mice. In all cases, drug was added to yield the next higher concentration, only when the response to the earlier dose reached a steady state. For 20-HETE, a single concentration (10 Ϫ7 M) was used. In experiments in which the effect of an antagonist was studied, it was added 30 min before contraction of the tissue with PE and was present throughout the experiments. Contraction/relaxation responses were expressed as a percentage increase/decrease in the contraction with respect to PE (alone) in response to each concentration of agonist used. The effect of methylsulfonyl-propargyloxyphenylhexanamide (MS-PPOH; 10 Ϫ5 M) was studied in PE-precontracted tissues using this protocol. The concentration of drugs was chosen on the basis of previous studies (4, 27, 31 Ϫ6 M CCPA at 37°C for 60 min. For experiments with the Cyp4a inhibitor, tissues were first incubated for 30 min with HET0016 (10 Ϫ5 M), followed by treatment with CCPA (10 Ϫ6 M) for 60 min. Each sample was homogenized with 130 l RIPA buffer on wet ice. The samples were transferred to dry ice for 5 min and then thawed on wet ice. After thawing, the samples were vortexed and centrifuged for 5 min at 12,000 rpm at 4°C. Supernatants were sonicated and stored at Ϫ80°C. Protein was measured using Bio-Rad assay based on the Bradford dye procedure with bovine serum albumin as a standard. The protein mixture was divided into aliquots and stored at Ϫ80°C. At the time of analysis, samples were thawed, and 30 g of total protein per lane were loaded on a slab gel. Proteins were separated by SDS-PAGE using 10% acrylamide gels (1-mm thick). After electrophoresis, the proteins on the gel were transferred to nitrocellulose membrane (Hybond-ECL) by electroelution. Protein transfer was confirmed by employing prestained molecular weight markers (Bio-Rad Laboratories, Hercules, CA). Following blocking with either 5% nonfat dry milk or BSA, the nitrocellulose membranes were incubated with primary antibody (A1AR, Cyp4a, PKC-␣, and p-ERK 1/2). 1:1,000 primary antibody concentrations were used for A1AR, Cyp4a, and PKC-␣, while 1:500 dilutions were used for total ERK and phosphorylated-ERK1/2 (p-ERK1/2). For Cyp2c29, a 1:5,000 antibody concentration was used. ␤-Actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was used as an internal control to normalize the target protein expression in each lane. The secondary antibody was a horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG. The membranes were developed using enhanced chemiluminescence (Amersham BioSciences) and exposed to X-ray film for the appropriate time. The data are presented as the normalized ratio (%change) of target protein to WT protein expression.
Drugs and chemicals. Acetylcholine and PE were dissolved in distilled water. DPCPX, CGS-21680, CCPA, chelerythrine chloride, angiotensin II, PD-98059, Gö-6976 (Calbiochem, La Jolla, CA), as well as 20-HETE and HET0016 (Cayman Chemical, Ann Arbor, MI), were dissolved in 100% DMSO as a 10 mM stock solution. MS-PPOH (Cayman Chemical, Ann Arbor, MI) was dissolved 100% ethanol as a 10 mM stock solution. The final concentration of DMSO in organ bath (10 ml) had no effect by itself on the aortic rings (2). PKC-␣ monoclonal antibody was purchased from BD Transduction Laboratories (San Diego, CA). ERK and ␤-actin antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Cyp4a antibody (which possibly recognizes Cyp4a1, Cyp4a10, Cyp4a14, and Cyp4a3 isoforms, according to the manufacturer) was obtained from Abcam (Cambridge, MA), and Cyp2c29 antibody was obtained from Dr. Darryl Zeldin (National Insti-tute of Environmental Health Sciences/National Institutes of Health). Unless stated otherwise, all chemicals were of the highest grade available and were purchased from Sigma Chemicals (St. Louis, MO).
Statistical analysis. The data are expressed as means Ϯ SE. Comparisons among different groups were analyzed by either oneway or two-way ANOVA (analysis of variance), followed by Tukey's multiple-comparison test or Bonferroni's post hoc test, respectively. Comparison between two groups was assessed by unpaired t-test. A P value of Ͻ0.05 was considered as the level of significance for all statistical tests. All of the statistical analyses were performed using GraphPad Prism statistical package.
RESULTS
Acetylcholine-dependent response in WT and A 2A KO mouse aorta. A 2A KO mice had significantly lower vascular relaxation (ϳ49%) to acetylcholine compared with respective WT on a C57BL/6J background (ϳ62%; P Ͻ 0.05; Fig. 1 ). This is similar to what has been reported (on CD-1 background strain) from this laboratory earlier (27, 31) .
Effect of CYP epoxygenase inhibitor (MS-PPOH) on CGS-21680-induced vascular response.
The vascular response to CGS-21680 (selective A 2A AR agonist) was studied in WT and A 2A KO mice aorta. Maximum response (20% relaxation) to CGS-21680 was observed in WT aorta at 10 Ϫ6 M (Fig. 2) , while A 2A KO did not respond at all (data not shown). We also determined the contribution of the endothelium to A 2A ARmediated relaxation, by performing concentration response with CGS-21860 in WT in which the endothelium has been removed (-E). Removal of the endothelium abolished CGS-21860-induced relaxation, suggesting that endothelium was involved in A 2A receptor-mediated relaxation.
In the intact endothelium of WT, the relaxation to CGS-21680 was significantly inhibited by MS-PPOH (10 Ϫ5 M), and the response changed from relaxation of 19.02 Ϯ 2.75% to contraction of 8.31 Ϯ 5.9% at 10 Ϫ6 M (P Ͻ 0.05; Fig. 2 ). MS-PPOH had no effect in the absence of endothelium. These data suggest that the involvement of endothelium through CYP epoxygenases causes A 2A -mediated relaxation and confirmed our laboratory's previous findings (26, 31) , which were observed in a different strain (CD-1) of A 2A KO and WT mice.
Effects of PKC blocker (chelerythrine chloride), selective PKC-␣ inhibitor (Gö-6976), p42/p44 MAPK inhibitor (PD-98059), and 20-HETE inhibitor (HET0016) on CCPA-induced vascular response.
The present data also showed a concentration-dependent response to CCPA (selective A 1 AR agonist) in both A 2A KO and WT aorta, with the KO having significantly higher contraction than WT (Fig. 3) . The maximum contraction produced by CCPA (10 Ϫ7 M) was 51.7 Ϯ 8.27% in KO compared with WT (29.01 Ϯ 4.3%; P Ͻ 0.05; Fig. 3 (Fig. 3B) Angiotensin II concentration response in WT and A 2A KO mouse aorta. The aortic response to angiotensin II was studied in aortas from WT and A 2A KO mice. Angiotensin II is known to activate the MAPK/PKC signaling pathways, and hence this experiment was done to support the involvement of MAPK/ PKC signaling in our experiments. We found that angiotensin II produced concentration-dependent contraction in both WT and KO aorta, with A 2A KO showing significantly higher contraction than WT (P Ͻ 0.05; Fig. 5) .
Expression of A 1 AR, Cyp2c29, and Cyp4a proteins in A 2A KO and WT mouse aorta. The expression of A 1 AR (ϳ37 kDa; Fig. 6A ) was ϳ41% higher in A 2A KO (141.23 Ϯ 9.67%; P Ͻ 0.05) compared with WT (100 Ϯ 11.81%). The expression of Cyp2c29 (ϳ50 kDa; Fig. 6B ) was ϳ32% lower (68.44 Ϯ 8.83% in A 2A KO; P Ͻ 0.05) compared with WT (100 Ϯ 5.95%). Also, Cyp4A (ϳ50 kDa; Fig. 5C ) was ϳ18% higher in A 2A KO (117.6 Ϯ 6.94%; P Ͻ 0.05) compared with WT (100 Ϯ 2.98%).
Protein expression of PKC-␣ in A 2A KO and WT mouse aorta. The expression of PKC-␣ (ϳ80 kDa) was ϳ66% higher in A 2A KO (165.6 Ϯ 8.05%; P Ͻ 0.05) compared with WT (100 Ϯ 13.99%; Fig. 7A ). CCPA (10 Ϫ6 M) increased PKC-␣ expression in WT by ϳ55% (from 100 Ϯ 13.99 to 154.84 Ϯ 12.81%; P Ͻ 0.05) while HET0016 (10 Ϫ5 M) reduced the CCPAinduced PKC-␣ expression by ϳ36% (from 154.84 Ϯ 12.81 to 118.77 Ϯ 4.35%; P Ͻ 0.05; Fig. 7B) . Similarly, in A 2A KO, CCPA increased expression of PKC-␣ by ϳ20% (from 100 Ϯ 4.86 to 119.7 Ϯ 6%; P Ͻ 0.05), while HET0016 reduced the CCPA-induced PKC-␣ expression by ϳ33% (from 119.7 Ϯ 6 to 86.66 Ϯ 4.65%; P Ͻ 0.05; Fig. 7C ). We also studied the effect of HET0016 alone and found there was no significant difference in expression of PKC-␣ between control and HET0016 treated aorta (WT: 100 Ϯ 26.61% vs. Fig. 8A ) was ϳ43% higher in A 2A KO (142.51 Ϯ 3.72%; P Ͻ 0.05) compared with WT (100 Ϯ 10%). CCPA (10 Ϫ6 M) increased p-ERK1/2 expression in WT by ϳ42% (from 100 Ϯ 10% in control to 141.6 Ϯ 4.92%; P Ͻ 0.05 compared with WT control), while HET0016 (10 Ϫ5 M) inhibited the CCPA-induced increase in p-ERK1/2 expression by ϳ25% (from 141.6 Ϯ 4.92 to 117.08 Ϯ 9.17%; Fig. 8B ). Similarly in A 2A KO, CCPA increased expression of p-ERK1/2 by 13% (from 100 Ϯ 2.61% in control to 113.44 Ϯ 5.5%; P Ͻ 0.05), while HET0016 reduced the CCPA-induced increase in expression by ϳ16% (from 113.44 Ϯ 5.5% to 97.73 Ϯ 2.56%; P Ͻ 0.05; Fig. 8C ). HET0016 by itself had no effect in expression of p-ERK1/2 in aorta (WT: 100 Ϯ 23.51% vs. WT ϩ HET0016 treated: 92.68 Ϯ 24.66%; n ϭ 4; A 2A KO: 100 Ϯ 16.95% vs. A 2A KO ϩ HET0016 treated: 102.33 Ϯ 18.93%; n ϭ 4).
DISCUSSION
The principal finding of this study supports the involvement of Cyp4a (via 20-HETE) through upregulation of A 1 AR, leading to the activation of PKC-␣ and MAPK (ERK1/2) and ultimately causing vascular contraction in A 2A AR KO mice (Fig. 9) . The endothelium plays a vital role in adenosine-mediated vascular responses, in both contraction and relaxation (2, 3, 25, 27, 32) . Many studies have reported that these effects are either completely endothelium-dependent/independent, or partially endothelium-dependent in various isolated vessels (2, 3, 29, 39, 46) . It has been found that the A 2A AR contributes to vascular relaxation through an endothelium-dependent mechanism in aorta and other vascular tissues (1, 23-25, 27, 32, 34, 35) . Upregulation of Cyp2c29 is also associated with A 2A AR in the endothelium-dependent relaxation to adenosine (adenosine 5=-N-ethylcarboxamide and CGS-21680) in aorta (27) . In our study, we found that A 2A KO had significantly lower response to acetylcholine compared with WT ( Fig. 1) , as well as lower expression of Cyp2c29 (Fig. 6B) , confirming our laboratory's previous findings (27, 32 ) that were obtained using a different strain of mice (CD1). WT aorta had a maximum response of 20% relaxation at the highest concentration of CGS-21680 (Fig. 2) , while A 2A KO aorta did not respond (data not shown). Removal of the endothelium abolished the CGS-21680-mediated response (Fig. 2) . Repetition of some of these experiments was essential to establish baseline responses in C57BL/6J mice (background strain for A 2A KO).
One of the possible factors that may cause the endotheliumdependent response is CYP epoxygenase, which generates AA-derived metabolites in the form of EETs in the endothelium. These EETs have been proposed to act as EDHFs (9) . To determine whether CYP epoxygenase plays any role in the CGS-21680-induced response, we used MS-PPOH, a selective CYP epoxygenase inhibitor. CGS-21860-induced relaxation in WT aorta changed to contraction with MS-PPOH, while it had no effect when the endothelium was removed (Fig. 2) . These data confirmed that endothelial epoxygenases were involved in CGS-21680-induced relaxation. Similar findings have been reported by other laboratories as well as us (5, 27, 28) .
The A 1 receptor is believed to mediate contraction in mouse aorta (33, 44) . In our laboratory's previous study, we found that the treatment of A 2A KO aorta with a selective A 1 AR antagonist, DPCPX, lowered the magnitude of contraction to adenosine 5=-N-ethylcarboxamide, which is a nonselective adenosine analog (32) . This indicated a role for A 1 AR in increased vascular contraction that was observed in A 2A KO aorta. In the present study, we examined the effects of CCPA, a selective A 1 agonist in WT and A 2A KO aorta (Fig. 3) . CCPA induced significantly higher contraction in A 2A KO aorta compared with WT. Western blot analysis also confirmed higher basal A 1 AR protein expression in A 2A KO (Fig. 6A) .
Studies from other laboratories have shown the involvement of MAPK (ERK1/2) signaling pathway downstream to A 1 AR activation (14, 31) . Recently, our laboratory has also shown a possible role for PKC-␣ upstream of ERK1/2 signaling in A 1 -mediated vascular contraction (4).
To determine whether PKC played any role in CCPAinduced contraction in A 2A KO and WT mice, we treated aorta with a nonspecific PKC blocker chelerythrine chloride, which inhibits all PKC isoforms, and then performed concentration response to CCPA. The PKC blocker significantly lowered contraction in both WT and A 2A KO tissues, suggesting that PKC may play a role in the signaling cascade downstream of A 1 AR activation (Fig. 3) . We then used a selective PKC-␣ inhibitor Gö-6976 to determine whether this particular isoform was involved in CCPA-induced contraction and found that inhibition of PKC-␣ significantly attenuated the contraction response to CCPA in both WT and A 2A KO aorta. Our data indicated that PKC-␣ is involved in A 1 AR-mediated aortic contraction.
To confirm the role of p42/p44 MAPK (ERK1/2), we used PD-98059 (p42/p44 MAPK inhibitor) to pretreat tissues, followed by concentration response to CCPA. Response to CCPA was completely blocked with the use of PD-98059 in both WT and A 2A KO aorta, suggesting that ERK1/2 is involved in A 1 -mediated contraction. Inhibition of CCPA-induced contraction with chelerythrine chloride was less compared with PD- 98059, suggesting the involvement of other signaling molecules upstream of ERK1/2, in addition to PKC. 20-HETE is an AA-derived metabolite synthesized in the presence of Cyp4a, and it is a potent vasoconstrictor (35) . HET0016 blocks Cyp4a activity and thereby inhibits the synthesis of 20-HETE in vasculature (15) . We determined the effect of HET0016 on CCPA-induced vascular response in A 2A KO and WT aorta and found that CCPA-induced vascular contraction was significantly reduced (Fig. 3) . These findings suggest that Cyp4a was involved in mediating the vasoconstriction through A 1 AR. Western blot analysis confirmed these findings and showed that A 2A KO mice had higher basal protein expression for both Cyp4a and A 1 AR compared with WT (Fig.  6, A and C) . These data, along with lowered Cyp2c29 expression in A 2A KO (Fig. 6B) , as well as the findings reported earlier by Nayeem et al. (27) , suggest that, in the absence of A 2A AR, there is an imbalance between CYP epoxygenases and -hydroxylases that leads to greater vascular contraction through upregulation of A 1 AR in A 2A KO.
We also investigated the effect of 20-HETE itself on vascular tone in A 2A KO and WT tissues (Fig. 4) to determine whether aortic responses to the -hydroxylation product were different. We used a single concentration of 20-HETE, based on literature (11) . A 2A KO had significantly higher contraction to 20-HETE than WT (Fig. 4) . Our next aim was to determine whether 20-HETE was linked to ERK1/2 and PKC-␣ signaling. We pretreated aortas taken from A 2A KO and WT mice with ERK1/2 inhibitor PD-98059 (Fig. 4A ) and selective PKC-␣ inhibitor Gö-6976 (Fig. 4B) . The 20-HETE response was blocked by PD-98059 and Gö-6976, respectively, suggesting that there is a link between Cyp4a, PKC-␣, and ERK1/2.
Angiotensin II is known to activate MAPK/PKC pathway (22) , and we performed angiotensin II concentration response in WT and A 2A KO mouse aortas to confirm the possibility of upregulation of MAPK/PKC in A 2A KO aorta (Fig. 5) . We found that A 2A KO had significantly higher angiotensin IImediated contraction compared with WT. These data confirm the downstream signaling mechanisms being similar to angio- tensin II and A 1 AR-mediated contraction. Taken together with the Western blot data that showed significantly higher basal levels of p-ERK1/2 ( Fig. 8A ) and PKC-␣ (Fig. 7A ) in control A 2A KO aorta compared with WT, these data suggest that there is upregulation of MAPK/PKC signaling in A 2A KO aorta.
ARs are coupled to many signaling pathways through G proteins, which include MAPKs. ERK1/2 is part of the MAPK family that regulates several physiological functions, like cell growth and differentiation, through various classes of receptors, including G protein-coupled receptors (30, 38) . ERK1/2 is activated by all four ARs (40), and our laboratory has shown that the activation of ERK1/2 is dependent on PKC-␣ activity through A 1 AR (4). We performed Western blot experiments using nontreated, CCPA-treated, and CCPA ϩ HET0016-treated A 2A KO and WT aortas. Based on the data from the current investigation and previous studies (4, 14, 26, 36) , we probed for PKC-␣ and p-ERK1/2 proteins (Figs. 7 and 8) . Studies have reported that 20-HETE is linked to PKC activation (14) , and the exogenous application of 20-HETE increases the phosphorylation of PKC-␣ (36) . PKC-␣ is also linked to A 1 AR-mediated signaling, as our laboratory has reported earlier (4) .
The basal protein expression of PKC-␣ and p-ERK1/2 was higher in A 2A KO compared with WT. Furthermore, we have shown, in the present study, that CCPA-treated A 2A KO and WT mouse aorta had a significant increase in p-ERK1/2 and PKC-␣ proteins, suggesting the involvement of ERK1/2 and PKC signaling in response to A 1 AR activation in A 2A KO (Figs. 7 and 8) . The data regarding the involvement of ERK1/2 and PKC isoforms through A 1 AR activation are supported by the use of PD-98059, chelerythrine chloride, and Gö-6976 (PKC-␣ inhibitor) in our organ bath studies, which blocked the CCPA-induced vascular response in A 2A KO and WT mouse aorta. HET0016 inhibited the CCPA-induced increase in protein expressions (PKC-␣ and p-ERK1/2) in both WT and A 2A KO mice. The HET0016-treated protein expression data, along with the functional (organ bath) studies using 20-HETE, suggest a relationship exists among A 1 AR, Cyp4a, PKC, and MAPK signaling.
Perspectives and Significance
The present study shows that the deletion of A 2A AR results in an upregulation of A 1 AR and Cyp4a, accompanied by downregulation of CYP epoxygenase (Cyp2c29). The A 2A KO mouse aorta has lower endothelial function compared with WT and has higher contraction to A 1 AR agonist and 20-HETE. The data from this study also suggest that PKC-␣ and p42/p44 MAPK play important roles in the signaling pathway, leading to vasoconstriction through upregulation of A 1 AR and Cyp4a in A 2A KO mice. In the present study, we used mouse aorta, which is a conduit vessel. This is a limitation of our study. However, in another unpublished study from our laboratory, the preliminary data showed no significant differences between the aortic vs. mesenteric responses with CCPA in A 2A KO compared with WT mice (45) .
AA-derived metabolite, 20-HETE, has a role in vasoconstriction, whereas A 2A AR plays a role in vasodilation. Both of these factors have roles in the regulation of vascular tone, and hence understanding how these two interact could give important insights into pathways involved in vascular signaling. Due to the heterogeneity of the vascular tissue (smooth muscle and endothelial cells) used in our studies, further investigations will be necessary to confirm the detailed signaling mechanisms by which the absence of A 2A AR upregulates A 1 AR, which modulates vasoconstriction, probably with the use of isolated endothelial and smooth muscle cells from the vascular tissue. A better understanding of these signaling pathways may lead to better approaches for the therapeutic interventions in vascular disorders.
